Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

← catalyst calendar

NCT05257551 · readout ≤ 955 d

Sponsored by Tempus AI (industry) · TEM — their whole pipeline →. With AstraZeneca.

Phase
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
11
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-07-13actualWhen the study began enrolling
Primary completionMar 2029estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionMar 2029estimatedThe whole study's end, after follow-up
First posted2022-02-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-15actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Small Cell Lung Cancer

Intervention

  • Other: Observation

Primary outcomes

what the primary-completion date above is the date OF
To determine if tumor tissue transcriptional subtypes can be detected
measured Up to 4 years
To characterize relationship between tissue transcriptional subtype and clinical outcomes
measured Up to 4 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed